• Piri Keşif Aracı

Arama ipuçları nelerdir?
1.  sayfa ve
1
Therapeutic potentials of fisetin, hesperetin and vitexin on chronic myeloid leukemia and acute myeloid leukemia cells
Tez

Tez
Open Access
Kaynak :
YÖK Tez Merkezi
Yazar(lar) :
AYSUN ADAN GÖKBULUT
Konu :
Biyoloji
Yıl :
2015
Therapeutic potentials of fisetin, hesperetin and vitexin on chronic myeloid leukemia and acute myeloid leukemia cells fisetin and hesperetin-induced effects. and CML for the first time. Moreover, the genetic networks derived from this study illuminate some of the biological pathways affected by fisetin and hesperetin treatment while providing
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Türkçe Özet :
Fisetin, hesperetin ve viteksin bitkilerde yaygın olarak bulunan flavonoid'lerdir. Bu çalışmada fisetin, hesperetin ve viteksinin HL60 APL and K562 KML hücreleri üzerindeki sitotoksik, apoptotik ve sitostatik etkilerinin incelenmesi amaçlanmaktadır. Bu üç flavonoid'in APL ve KML üzerindeki etkilerini gösteren herhangi bir çalışma bulunmamaktadır. Bu çalışmada ayrıca tüm genom mikroçip analizi yapılarak fisetin ve hesperetin ile muamele edilen APL ve KML hücrelerinde değişime uğrayan genler ve sinyal iletim yollarının belirlenmesi amaçlanmıştır. Özet olarak, söz konusu flavonoid lerin APL ve KML hücreleri üzerindeki etkilerinin moleküler mekanizmaları ve global gen ifadesindeki değişikliklerin ilk defa gösterilmesi amaçlanmıştır. Fisetin, hesperetin ve viteksin ile muamele edilen K562 KML ve HL60 APL hücrelerinde doza ve zamana bağımlı olarak hücre canlılığında bir azalma olduğu gösterilmiştir. Her iki hücre tipinde apoptozun tetiklenmesinde en etkili ajanın fisetin olduğu saptanmıştır. Ayrıca, fisetin, hesperetin ve viteksinin her iki hücre tipinde hücre döngüsünün farklı safhaları üzerinde etkili olduğu dolayısyla sitostatik etkiye sahip olduğu gösterilmiştir. Sonuç olarak, fisetin ve hesperetinin hücre çoğalmasını inhibe etmeleri, apoptozu tetiklemeleri ve hücre döngüsünün çeşitli safhalarında tutulmalara neden olmalarından dolayı hem KML hem de APL tedavisinde terapötik potansiyellerinin olabileceği düşünülmektedir. Ayrıca, tüm genom mikroçip analizinden elde edilen sonuçlar fisetin ve hesperetin muamelesi sonucu etkilenen biyolojik yolakların ve bu yolaklarda görev alan molekülleri kodlayan genlerin tanımlanmasını sağlamıştır. Bu genlerin hedeflenerek KML ve APL tedavisinde kullanılabileceği düşünülmektedir.
İngilizce Başlık : Fisetin, hesperetin ve viteksin'in kronik miyeloid lösemi ve akut miyeloid lösemi hücreleri üzerine terapötik potansiyelleri
İngilizce Özet :
Fisetin, hesperetin and vitexin are plant-derived flavonoids. This thesis study aims to investigate therapeutic potentials of them on human HL60 APL and K562 CML cells since there are no studies on these cells. The effects of these compounds on APL and CML cells have been considered in terms of cytotoxicity, apoptosis and cell cycle progression. In this study, genome-wide microarray analysis has been also performed for APL and CML cells to identify the genes and networks that are responsible for fisetin and hesperetin-induced effects. In summary, we intented to explain the molecular mechanisms and global gene expression patterns related with the effects of these flavonoids on both APL and CML for the first time. There were decreases in the viability/proliferation of K562 and HL60 cells treated with fisetin, hesperetin and vitexin. Fisetin was the most effective flavonoid for the induction of apoptosis in both cells. Fisetin, hesperetin and vitexin have been found to affect cell cycle progression at different phases of the cell cycle in both CML and AML cells, thus having cytostatic effects. In conclusion, the results of this study indicated that especially fisetin and hesperetin may have therapeutic potential in APL and CML cells due to induction of apoptosis, inhibition of cell proliferation and cell cyle arrest. Moreover, the genetic networks derived from this study illuminate some of the biological pathways affected by fisetin and hesperetin treatment while providing a proof of principle for identifying candidate genes that might be targeted for CML and APL therapy.
Anahtar Kelimeler : Kanser hücreleri, Lösemi, Flavonlar
2
Molecular Emergence of Acute Myeloid Leukemia during Treatment for Acute Lymphoblastic Leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
JSTOR
Dergi:
Proceedings of the National Academy of Sciences of the United States of America
Yayıncı:
National Academy of Sciences
Yazar(lar) :
Javier G. Blanco , Thierry Dervieux , Mathew J. Edick , Perdeep K. Mehta , Jeffrey E. Rubnitz , Sheila Shurtleff , Susana C. Raimondi , Frederick G. Behm , Ching-Hon Pui , Mary V. Relling
Konu :
Biological Sciences, Science & Mathematics, General Science
Yıl :
2001
Molecular Emergence of Acute Myeloid Leukemia during Treatment for Acute Lymphoblastic Leukemia Therapy-related acute myeloid leukemias (t-AML) with translocations of the MLL gene are associated with the use of topoisomerase II inhibitors. We established the emergence of the malignant clone in a child who developed t-AML with a t(11;19) (q23;p13.3) during treatment for acute lymphoblastic leukemia (ALL).
Yayıncı Web Sitesi
Kaydet Alıntıla
Therapy-related acute myeloid leukemias (t-AML) with translocations of the MLL gene are associated with the use of topoisomerase II inhibitors. We established the emergence of the malignant clone in a child who developed t-AML with a t(11;19) (q23;p13.3) during treatment for acute lymphoblastic leukemia (ALL). The MLL-ENL and the reciprocal ENL-MLL genomic fusions and their chimeric transcripts were characterized from samples collected at the time of t-AML diagnosis. We used PCR with patient-specific genomic primers to establish the emergence of the MLL-ENL fusion in serially obtained DNA samples. The MLL-ENL fusion was not detectable in bone marrow at the time of ALL diagnosis or after 2 months of chemotherapy (frequency <8.3 × 10-7 cells-1). The genomic fusion was first detected in bone marrow after 6 months of treatment at a frequency of one in 4,000 mononuclear bone marrow cells; the frequency was one in 70 cells after 20 months of therapy. At the first detection of MLL-ENL, the only topoisomerase II inhibitors the patient had received were one dose of daunorubicin and two doses of etoposide. The MLL-ENL fusion was not detectable in blood at the time of ALL diagnosis or after 0.7, 2, 8, 10, and 12 months of therapy but was detectable in blood at 16 months (one in 2.3 × 104 cells). Recombinogenic Alu sequences bracketed the breakpoints in both fusions. These data indicate that the malignant clone was not present before therapy, arose early during chemotherapy, and was able to proliferate even during exposure to antileukemic therapy.
Cilt: 98
Sayı: 18
Sayfa: pp. 10338-10343
Yayın Tarihi: 2001-08-28
ISSN: 0027-8424
3
Childhood Acute Myeloid Leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Current Treatment Options in Oncology
Yazar(lar) :
Jeffrey E. Rubnitz
Konu :
Pharmacology (medical), Oncology
Yıl :
2008
Childhood Acute Myeloid Leukemia Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia Instead, advances in the treatment of children with AML will require a greater understanding of the biology of the disease, with particular attention to More important, we must develop alternative treatment approaches, such as agents that target specific leukemia-associated abnormalities and agents that Current Treatment Options in Oncology Acute Myeloid Leukemia Acute Myeloid Leukemia Patient
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia (AML) still suffer relapse of their disease. It is unlikely that improvements in outcome can be achieved by further intensification of conventional chemotherapy. Instead, advances in the treatment of children with AML will require a greater understanding of the biology of the disease, with particular attention to the genetic abnormalities underlying leukemogenesis and drug resistance. Future clinical trials should include refined risk-directed therapy based on the genetics of the leukemic blasts and the patient’s response to therapy. More important, we must develop alternative treatment approaches, such as agents that target specific leukemia-associated abnormalities and agents that selectively eradicate leukemic stem cells.
DOI : 10.1007/s11864-008-0059-z
Anahtar Kelimeler : Acute Myeloid Leukemia, Minimal Residual Disease, Acute Myeloid Leukemia Patient, Gemtuzumab Ozogamicin, Clofarabine
ISSN: 1527-2729 1534-6277
Sayı: 1
Cilt: 9
Sayfa: 95-105
4
Acute myeloid leukemia
Kitap Bölümü

Kitap Bölümü
Kaynak 1:
Wiley Online Library
Kaynak 2:
Wiley Online Library
Kaynak 3:
Wiley Online Library
Kaynak 4:
Wiley Online Library
Dergi:
Evidence-Based Pediatric Oncology
Yayıncı:
John Wiley & Sons, Ltd
Yazar(lar) :
Ananth Shankar
Yıl :
2013
Acute myeloid leukemia To evaluate whether a lower dose of prophylactic cranial irradiation in children with acute myeloid leukemia (AML) is sufficient to prevent central nervous system (CNS) relapse of leukemia. Patients with Down syndrome, CNS leukemia at diagnosis, not in complete remission after 140 days of treatment or those assigned to stem cell transplantation
Tam Metin
Kaydet Alıntıla
To evaluate whether a lower dose of prophylactic cranial irradiation in children with acute myeloid leukemia (AML) is sufficient to prevent central nervous system (CNS) relapse of leukemia. Patients with Down syndrome, CNS leukemia at diagnosis, not in complete remission after 140 days of treatment or those assigned to stem cell transplantation were excluded from trial enrollment. The main analysis was performed on actual treatment received rather than on an intention‐to‐treat principle. Survival outcomes were estimated using the KaplanMeier method with standard errors according to Greenwood, and were compared with the log‐rank test. It was concluded that 12 Gy cranial irradiation was as effective as 18 Gy in preventing CNS relapse in children with AML.
DOI : 10.1002/9781118625309.ch17
ISBN:9780470659649
Sayfa: 144-145
5
ACUTE MYELOID LEUKEMIA: TREATMENT OVER 60
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Reviews in Clinical and Experimental Hematology
Yazar(lar) :
Thomas Buchner , Wolfgang Hiddemann , Wolfgang Berdel , Bernhard Wormann , Claudia Schoch , Helmut Loffler , Torsten Haferlach , Andrea Schumacher , Peter Staib , Leopold Balleisen , Andreas Gruneisen , Herbert Rasche , Carlo Aul , Axel Heyll , Eva Lengfelder , Wolf-Dieter Ludwig , Georg Maschmeyer , Hartmut Eimermacher , Jochen Karow , Norbert Frickhofen , Wolf-Dietrich Hirschmann , Maria-Cristina Sauerland
Konu :
Hematology
Yıl :
2002
ACUTE MYELOID LEUKEMIA: TREATMENT OVER 60 Undertreatment of older patients with acute myeloid leukemia (AML) can explain, in part, their inferior outcome when compared to that of younger patients and for the duration of postremission treatment. A questionnaire study in patients with AML showed that, according to patients’ self‐assessment, intensive and prolonged treatment did not result in a diminished Reviews in Clinical and Experimental Hematology
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Undertreatment of older patients with acute myeloid leukemia (AML) can explain, in part, their inferior outcome when compared to that of younger patients. In agreement with the benefit seen by patients under age 60 from high‐dose cytosine arabinoside (Ara‐C), there are dose effects in the over 60s, in particular for daunorubicin, in induction treatment and for the duration of postremission treatment. The use of these effects can partly overcome the mostly unfavorable disease biology in older age AML, as expressed by the absence of favorable and the over‐representation of adverse chromosomal abnormalities as well as the expression of drug resistance. We recommend an adequate dosage of 60 mg/m2 daunorubicin on 3 days in combination with standard dose Ara‐C and 6‐thioguanine given for induction and consolidation, and followed by a prolonged monthly maintenance chemotherapy for at least 1 year's duration. Further improvements in supportive care may help to deliver additional antileukemic cytotoxicity. As a novel approach, nonmyeloablative preparative regimens may open up the possibility of allogeneic transplantation for older patients with AML. Other new options like multidrug resistance modulators, antibody targeted therapies and molecular targeting are under clinical investigation. A questionnaire study in patients with AML showed that, according to patients’ self‐assessment, intensive and prolonged treatment did not result in a diminished quality of life. This finding did not vary by age, under or over 60 years. As the median age in this disease is more than 60 years, the adequate management of AML in older patients remains the major challenge.
DOI : 10.1046/j.1468-0734.2002.00059.x
ISSN: 1127-0020
Sayı: 1
Cilt: 6
Sayfa: 46-59
6
Maintenance treatment in acute myeloid leukemia
Kitap Bölümü

Kitap Bölümü
Kaynak :
Wiley Online Library
Dergi:
Evidence-Based Pediatric Oncology
Yayıncı:
John Wiley & Sons, Ltd
Yazar(lar) :
Ananth Shankar
Yıl :
2013
Maintenance treatment in acute myeloid leukemia The use of postremission low‐dose maintenance treatment (MT) in childhood acute myeloid leukemia (AML) has yielded mixed results. The studies by Perel et al. and Wells et al. suggest that MT does not appear to improve overall survival (OS). The acute promyelocytic leukemia (APL) 93 trial was a randomized European study evaluating postremission therapy for patients with APL.
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
The use of postremission low‐dose maintenance treatment (MT) in childhood acute myeloid leukemia (AML) has yielded mixed results. This chapter provides a summary of previous studies. The studies by Perel et al. and Wells et al. suggest that MT does not appear to improve overall survival (OS). The acute promyelocytic leukemia (APL) 93 trial was a randomized European study evaluating postremission therapy for patients with APL. A later study, the GIMEMA‐AIEOPAIDA trial, also evaluated the benefit of MT in childhood AML. MT with ATRA combined with CT improved survival outcome in children with APL although no conclusion can be drawn on the advantage of MT in APL due to early closure of the control arm.
DOI : 10.1002/9781118625309.ch15
ISBN:9780470659649
Sayfa: 137-140
7
Acute myeloid leukemia in infants: biology and treatment
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Frontiers in Pediatrics
Yazar(lar) :
Riccardo eMasetti , Francesca eVendemini , Daniele eZama , Carlotta eBiagi , Andrea ePession , Franco eLocatelli , Franco eLocatelli
Yıl :
2015
Acute myeloid leukemia in infants: biology and treatment Children aged 0–2 years (i.e. infants) with acute myeloid leukemia (AML) are a peculiar subgroup of patients in the childhood AML scenario. Remarkable improvements have been achieved over the last 2 decades in the treatment of these patients and their outcome is becoming superimposable to that Treatment results and toxicity data reported by major collaborative groups are also summarized and compared. acute myeloid leukemia (AML) Treatment results
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Children aged 0–2 years (i.e. infants) with acute myeloid leukemia (AML) are a peculiar subgroup of patients in the childhood AML scenario. They present with distinctive biological and clinical characteristics, including a high prevalence of prognostically unfavorable risk factors and an increased susceptibility to therapy-related toxicity. Remarkable improvements have been achieved over the last 2 decades in the treatment of these patients and their outcome is becoming superimposable to that of the older age groups. In this review, we will focus on peculiarities of this young subgroup of children with AML, describing their clinical presentation, the biology of disease and factors influencing outcome. Treatment results and toxicity data reported by major collaborative groups are also summarized and compared.
DOI : 10.3389/fped.2015.00037
Anahtar Kelimeler : Hematopoietic Stem Cell Transplantation, Toxicity, infants, acute myeloid leukemia (AML), prognostic factors, Treatment results
ISSN: 2296-2360
Cilt: 3
Sınıflandırma :
8
Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Chinese Medical Journal
Yazar(lar) :
Meng-Ge Yu , Hu-Yong Zheng
Yıl :
2017
Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment Objective: Leukemia is the most common pediatric malignancy and a major cause of morbidity and mortality in children. Among all subtypes, a lack of consensus exists regarding the diagnosis and treatment of acute myeloid leukemia (AML). Results: We described clonal evolution and how it changes our view on leukemogenesis, treatment responses, and disease relapse. Acute Myeloid Leukemia
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Objective: Leukemia is the most common pediatric malignancy and a major cause of morbidity and mortality in children. Among all subtypes, a lack of consensus exists regarding the diagnosis and treatment of acute myeloid leukemia (AML). Patient survival rates have remained modest for the past three decades in AML. Recently, targeted therapy has emerged as a promising treatment. Data Sources: We searched the PubMed database for recently published research papers on diagnostic development, target therapy, and other novel therapies of AML. Clinical trial information was obtained from ClinicalTrials.gov. For the major purpose of this review that is to outline the latest therapeutic development of AML, we only listed the ongoing clinical trials for reference. However, the published results of complete clinical trials were also mentioned. Study Selection: This article reviewed the latest developments related to the diagnosis and treatment of AML. In the first portion, we provided some novel insights on the molecular basis of AML, as well as provided an update on the classification of AML. In the second portion, we summarized the results of research on potential molecular therapeutic agents including monoclonal antibodies, tyrosine kinase/Fms-like tyrosine kinase 3 (FLT3) inhibitors, epigenetic/demethylating agents, and cellular therapeutic agents. We will also highlight ongoing research and clinical trials in pediatric AML. Results: We described clonal evolution and how it changes our view on leukemogenesis, treatment responses, and disease relapse. Pediatric-specific genomic mapping was discussed with a novel diagnostic method highlighted. In the later portion of this review, we summarized the researches on potential molecular therapeutic agents including monoclonal antibodies, tyrosine kinase/FLT3 inhibitors, epigenetic/demethylating agents, and cellular therapeutic agents. Conclusion: Gene sequencing techniques should set the basis for next-generation diagnostic methods of AML, and target therapy should be the focus of future clinical research in the exploration of therapeutic possibilities.
DOI : 10.4103/0366-6999.198004
Anahtar Kelimeler : Acute Myeloid Leukemia, Advancements, Diagnosis, Target Therapy
Cilt: 130
Sayı: 2
Sayfa: 211 - 218
Sınıflandırma :
Hematoloji %100
9
Characterization of MYC expression in gefitinib versus Acute Myeloid Leukemia reveals novel therapeutic targets
Konferans Bildirileri

Konferans Bildirileri
Kaynak :
IEEE Xplore
Yazar(lar) :
James F. Courage , Saurabh Gupta , Yufeng Wang
Konu :
Bioengineering, Computing and Processing
Yıl :
2007
Characterization of MYC expression in gefitinib versus Acute Myeloid Leukemia reveals novel therapeutic targets We conducted gene expression profiling and pathway analysis of microarray data generated from a gefitinib versus M4-AML study. findings indicate that a therapeutic reduction of the human v-Myc oncoprotein correlated to molecular reversal of cell transformation within 24 hours of treatment These targets, Src and Jnk3, demonstrated strong interactions with gefitinib in small molecule/tyrosine kinase binding assays and have proven critical Bioengineering,Computing and Processing 2007 IEEE 7th International Symposium on BioInformatics and BioEngineering Medical treatment acute myeloid leukemia Acute Myeloid Leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
We conducted gene expression profiling and pathway analysis of microarray data generated from a gefitinib versus M4-AML study. Our findings indicate that a therapeutic reduction of the human v-Myc oncoprotein correlated to molecular reversal of cell transformation within 24 hours of treatment. We analyzed the known efficacies of gefitinib and were able to identify bona fide gefitinib targets in the PDGFR pathway that we believe to be responsible for cell rescue. These targets, Src and Jnk3, demonstrated strong interactions with gefitinib in small molecule/tyrosine kinase binding assays and have proven critical to MYC induction in gene inhibition assays.
DOI : 10.1109/bibe.2007.4375637
Anahtar Kelimeler : Cancer, Medical treatment, Drugs, Humans, Amino acids, Bones, White blood cells, Hemorrhaging, Gene expression, Data analysis, biochemistry, blood, cellular biophysics, diseases, drugs, enzymes, genetics, medical computing, microorganisms, molecular biophysics, MYC expression, myelocytomatosis viral oncogene homolog, gefitinib, acute myeloid leukemia, therapeutic targets, gene expression profiling, pathway analysis, microarray data, oncoprotein, cell transformation, tyrosine kinase, binding assays, gene inhibition assays, Microarray, MYC, Gefitinib, Acute Myeloid Leukemia, SRC, JNK3, P38
10
Antibody-Based Treatment of Acute Myeloid Leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Current Hematologic Malignancy Reports
Yazar(lar) :
Phillip M. Garfin , Eric J. Feldman
Konu :
Cancer Research, Oncology, Hematology
Yıl :
2016
Antibody-Based Treatment of Acute Myeloid Leukemia While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid leukemia (AML). (ADCs), radio-labelled antibodies, and immune-engaging antibodies, and discusses the promise and challenges associated with each. Acute myeloid leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid leukemia (AML). More recently, improvements in antibody-drug conjugate technology, bispecific antibodies, as well as identification of novel AML antigens have re-invigorated enthusiasm for antibody-based therapies for AML. This review describes experiences with former and existing antibody-based therapies for AML, including unconjugated antibodies, antibody-drug conjugates (ADCs), radio-labelled antibodies, and immune-engaging antibodies, and discusses the promise and challenges associated with each.
DOI : 10.1007/s11899-016-0349-7
Anahtar Kelimeler : Acute myeloid leukemia, Antibody therapy, CD33, CD123, Immunotherapy
ISSN: 1558-8211 1558-822X
Sayı: 6
Cilt: 11
Sayfa: 545-552
11
Treatment strategies in acute myeloid leukemia (AML)
Dergi Makalesi

Dergi Makalesi
Kaynak 1:
Springer Link
Kaynak 2:
Springer Link
Yazar(lar) :
T. Buechner , W. Hiddemann
Konu :
Hematology, General Medicine, Hematology
Yıl :
1990
Treatment strategies in acute myeloid leukemia (AML) Chemotherapy remains the backbone of treatment in AML. Of all adult patients 65% go into remission and have a chance of longer survival and of even being cured. Improved antimicrobial treatment and the use of hematopoietic growth factors may help making multiple-step chemotherapy practicable, thereby increasing Acute myeloid leukemia
Tam Metin
Kaydet Alıntıla
Chemotherapy remains the backbone of treatment in AML. Of all adult patients 65% go into remission and have a chance of longer survival and of even being cured. Among the responders, 25% can be cured by intensive and long-term chemotherapy. Since the effect of chemotherapy appears not to be limited to a special period of time, its antileukemic and curative potential could be further exploited by multiple-step chemotherapy combining double induction, intensified consolidation and long-term maintenance. Improved antimicrobial treatment and the use of hematopoietic growth factors may help making multiple-step chemotherapy practicable, thereby increasing the cure rate in AML.
DOI : 10.1007/bf01720509
Anahtar Kelimeler : Acute myeloid leukemia, Induction, Consolidation, Maintenance, Elderly patients, Multiple-step chemotherapy, Hematopoietic growth factors
ISSN: 0006-5242 1432-0584
Sayı: 2
Cilt: 60
Sayfa: 61-67
12
Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Current Treatment Options in Oncology
Yazar(lar) :
Prithviraj Bose , Pankit Vachhani , Jorge E. Cortes
Konu :
Pharmacology (medical), Oncology
Yıl :
2017
Treatment of Relapsed/Refractory Acute Myeloid Leukemia Approximately 40–45% of younger and 10–20% of older adults with acute myeloid leukemia (AML) will be cured with current standard chemotherapy. In recent years, much has been learned about the genomic and epigenomic landscapes of AML, and the clonal architecture of both de novo and secondary AML In our practice, we treat most patients with relapsed/refractory AML on clinical trials, taking into consideration their prior treatment history and Current Treatment Options in Oncology
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Approximately 40–45% of younger and 10–20% of older adults with acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The outlook is particularly gloomy for patients with relapsed and/or refractory disease (cure rates no higher than 10%). Allogeneic hematopoietic stem cell transplantation (HSCT), the only realistic hope of cure for these patients, is an option for only a minority. In recent years, much has been learned about the genomic and epigenomic landscapes of AML, and the clonal architecture of both de novo and secondary AML has begun to be unraveled. These advances have paved the way for rational drug development as new “drugable” targets have emerged. Although no new drug has been approved for AML in over four decades, with the exception of gemtuzumab ozogamycin, which was subsequently withdrawn, there is progress on the horizon with the possible regulatory approval soon of agents such as CPX-351 and midostaurin, the Food and Drug Administration “breakthrough” designation granted to venetoclax, and promising agents such as the IDH inhibitors AG-221 and AG-120, the smoothened inhibitor glasdegib and the histone deacetylase inhibitor pracinostat. In our practice, we treat most patients with relapsed/refractory AML on clinical trials, taking into consideration their prior treatment history and response to the same. We utilize targeted sequencing of genes frequently mutated in AML to identify “actionable” mutations, e.g., in FLT3 or IDH1/2, and incorporate small-molecule inhibitors of these oncogenic kinases into our therapeutic regimens whenever possible. In the absence of actionable mutations, we rationally combine conventional agents with other novel therapies such as monoclonal antibodies and other targeted drugs. For fit patients up to the age of 65, we often use high-dose cytarabine-containing backbone regimens. For older or unfit patients, we prefer hypomethylating agent-based therapy. Finally, all patients with relapsed/refractory AML are evaluated for allogeneic HSCT.
DOI : 10.1007/s11864-017-0456-2
Anahtar Kelimeler : AML, Epigenetic therapy, Targeted therapy, FLT3 inhibitors, IDH inhibitors, Antibody-drug conjugates
ISSN: 1527-2729 1534-6277
Sayı: 3
Cilt: 18
13
Convolution Neural Network Models for Acute Leukemia Diagnosis
Konferans Bildirileri

Konferans Bildirileri
Kaynak :
IEEE Xplore
Yazar(lar) :
Maila Claro , Luis Vogado , Rodrigo Veras , Andre Santana , Joao Tavares , Justino Santos , Vinicius Machado
Konu :
Computing and Processing, Signal Processing and Analysis
Yıl :
2020
Convolution Neural Network Models for Acute Leukemia Diagnosis Acute leukemia is a cancer-related to a bone marrow abnormality. It is more common in children and young adults. This type of leukemia generates unusual cell growth in a short period, requiring a quick start of treatment. Acute Lymphoid Leukemia (ALL) and Acute Myeloid Leukemia (AML) are the main responsible for deaths caused by this cancer. Computing and Processing,Signal Processing and Analysis 2020 International Conference on Systems, Signals and Image Processing (IWSSIP) Acute Leukemia diagnosis Acute Lymphoid Leukemia Acute Myeloid Leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Acute leukemia is a cancer-related to a bone marrow abnormality. It is more common in children and young adults. This type of leukemia generates unusual cell growth in a short period, requiring a quick start of treatment. Acute Lymphoid Leukemia (ALL) and Acute Myeloid Leukemia (AML) are the main responsible for deaths caused by this cancer. The classification of these two leukemia types on blood slide images is a vital process of and automatic system that can assist doctors in the selection of appropriate treatment. This work presents a convolutional neural networks (CNNs) architecture capable of differentiating blood slides with ALL, AML and Healthy Blood Slides (HBS). The experiments were performed using 16 datasets with 2,415 images, and the accuracy of 97.18% and a precision of 97.23% were achieved. The proposed model results were compared with the results obtained by the state of the art methods, including also based on CNNs.
DOI : 10.1109/iwssip48289.2020.9145406
Anahtar Kelimeler : Computer architecture, Blood, Microprocessors, Support vector machines, Training, Computational modeling, Convolution, blood, bone, cancer, cellular biophysics, convolutional neural nets, medical image processing, neural net architecture, patient diagnosis, patient treatment, Acute Leukemia diagnosis, cancer, bone marrow abnormality, young adults, unusual cell growth, Acute Lymphoid Leukemia, Acute Myeloid Leukemia, AML, leukemia types, blood slide images, automatic system, convolutional neural networks architecture, healthy blood slides, leukemia diagnosis, convolutional neural network, computer aided diagnosis
14
Novel Treatment Paradigms in Acute Myeloid Leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Clinical Pharmacology & Therapeutics
Yazar(lar) :
Nabin Khanal , Shristi Upadhyay Banskota , Vijaya Raj Bhatt
Konu :
Pharmacology (medical), Pharmacology
Yıl :
2020
Novel Treatment Paradigms in Acute Myeloid Leukemia Acute myeloid leukemia (AML) is a heterogeneous disease marked by the presence of several driver mutations and molecular subgroups even in a single patient Cytogenetic results and somatic mutations are increasingly being utilized to guide use of intensive chemotherapy and low‐intensity chemotherapy, particularly The last 3 years mark an unprecedented history in the drug development in AML with approval of 8 new drugs and large portfolio of ongoing early and late‐phase
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Acute myeloid leukemia (AML) is a heterogeneous disease marked by the presence of several driver mutations and molecular subgroups even in a single patient. The genetic and molecular heterogeneity is also reflected by a progressive shift from a morphologic classification to one informed by causative genomic changes. Cytogenetic results and somatic mutations are increasingly being utilized to guide use of intensive chemotherapy and low‐intensity chemotherapy, particularly among older adults. Utilization of next‐generation sequencing in AML has led to increasing use of targeted treatments for actionable mutations. Quantitative real‐time polymerase chain reaction‐based mutational analysis and multicolor flow cytometry offer sensitive assays that can detect minimal residual disease (MRD). Several studies have shown that MRD negativity, as defined by specified cutoff values, is highly prognostic with potential therapeutic implications. The last 3 years mark an unprecedented history in the drug development in AML with approval of 8 new drugs and large portfolio of ongoing early and late‐phase trials of several promising drugs. Multiple combinatorial trials of approved agents and approval of newer agents in the future will continue to change the therapeutic landscape of AML.
DOI : 10.1002/cpt.1962
ISSN: 0009-9236
Sayı: 3
Cilt: 108
Sayfa: 506-514
15
Novel treatment for refractory acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Pediatric Transplantation
Yazar(lar) :
Olle Ringdén
Konu :
Pediatrics, Perinatology, and Child Health, Transplantation
Yıl :
2003
Novel treatment for refractory acute myeloid leukemia Pediatrics, Perinatology, and Child Health,Transplantation
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1046/j.1397-3142.2003.00106.x
ISSN: 1397-3142
Sayı: 6
Cilt: 7
Sayfa: 422-425
16
Treatment of Childhood Acute Myeloid Leukemia in Bulgaria
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Folia Medica
Yazar(lar) :
Burnusuzov Hasan A. , Yordanova Maya N. , Avramova Boryana E. , Yurukova Nadezhda N. , Bachvarov Konstantin N. , Muchinova Albena B. , Vlahova Irena H. , Stoyanova Angelina A. , Mumdzhiev Ivan N. , Ivanova Liliya R. , Spasov Neofit Y. , Peteva Elina Ts. , Belcheva Milena I. , Hristozova Hristina , Spasova Mariya I. , Kaleva Valeriya I. , Bobev Dragan , Konstantinov Dobrin N.
Yıl :
2018
Treatment of Childhood Acute Myeloid Leukemia in Bulgaria Background: During the last four decades the prognosis of childhood acute myeloid leukemia (AML) has been substantially improved due to an increase in complete remission (CR) rates, event-free survival (EFS) and reduced early mortality. acute myeloid leukemia children
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Background: During the last four decades the prognosis of childhood acute myeloid leukemia (AML) has been substantially improved due to an increase in complete remission (CR) rates, event-free survival (EFS) and reduced early mortality. The relapsed AML still remains a therapeutic challenge.
DOI : 10.1515/folmed-2017-0090
Anahtar Kelimeler : acute myeloid leukemia, children, relapse
Cilt: 60
Sayı: 2
Sayfa: 234 - 240
Sınıflandırma :
Hematoloji %100
17
Acute kidney injury and childhood acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Pediatric Nephrology
Yazar(lar) :
Chompoonut Limratchapong , Praewa Sophark , Prayong Vachvanichsanong , Edward B. McNeil , Thirachit Chotsampancharoen
Konu :
Nephrology, Pediatrics, Perinatology and Child Health
Yıl :
2022
Acute kidney injury and childhood acute myeloid leukemia Acute kidney injury (AKI) appears to be particularly common in children with acute myeloid leukemia (AML), although the epidemiology data on this patient The objective of this study was to assess the prevalence and factors associated with AKI in childhood AML during chemotherapy treatment. Age ≥ 10 years at diagnosis, impaired kidney function before treatment, and septic shock were strongly associated with AKI. Nephrology,Pediatrics, Perinatology and Child Health Acute kidney injury Childhood acute myeloid leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Acute kidney injury (AKI) appears to be particularly common in children with acute myeloid leukemia (AML), although the epidemiology data on this patient population is sparse. The objective of this study was to assess the prevalence and factors associated with AKI in childhood AML during chemotherapy treatment. The medical records of 112 children aged under 15 years diagnosed with AML who received chemotherapy in a major tertiary-care referral center in southern Thailand were reviewed. Logistic regression was used to identify factors associated with AKI. Fifty-six (50%) children had AKI events. The median time from AML diagnosis to the first AKI was 29.5 days (interquartile range: 11.0–92.8) and the median follow-up time was 10.9 months (interquartile range: 3.6–31.1). Age at diagnosis ≥ 10 years (OR 2.75, 95% CI 1.09–6.93), glomerular filtration rate < 90 mL/min/1.73 m2 at AML diagnosis (OR 7.58, 95% CI 1.89–30.5), and septic shock (OR 22.0, 95% CI 4.63–104.3) were independently associated with AKI. Childhood AML has a high rate of kidney injury with 50% having AKI. Age ≥ 10 years at diagnosis, impaired kidney function before treatment, and septic shock were strongly associated with AKI. A higher resolution version of the is available as Supplementary information.
DOI : 10.1007/s00467-022-05506-4
Anahtar Kelimeler : Acute kidney injury, Childhood acute myeloid leukemia, Oncology, Risk factor
ISSN: 0931-041X 1432-198X
18
Acute myeloid leukemia in adults
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Current Treatment Options in Oncology
Yazar(lar) :
Larry D. Cripe , Stuart Hinton
Konu :
Pharmacology (medical), Oncology
Yıl :
2000
Acute myeloid leukemia in adults The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. therapy for newly diagnosed patients with AML should consist of cytarabine (100 mg/m2 as a continuous intravenous infusion over 24 hours for 7 days) and Current Treatment Options in Oncology Acute Myeloid Leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction. Thus, induction therapy for newly diagnosed patients with AML should consist of cytarabine (100 mg/m2 as a continuous intravenous infusion over 24 hours for 7 days) and daunorubicin, darubicin, or mitoxantrone. Meta-analysis demonstrates a modest benefit for idarubicin. Most patients who achieve a remission should receive further therapy with two to four cycles of high-dose cytarabine. Allogeneic stem cell transplant is reserved for patients with poor risk features. There is no role for autologous stem cell transplant in first remission outside a clinical trial. The majority of adults relapse. Salvage therapy usually consists of high-dose cytarabine. Allogeneic or autologous stem cell transplantation is preferred in second or subsequent remission. Uncommon diseases such as AML, for which the outcome remains poor, should be treated on clinical trials whenever possible.
DOI : 10.1007/s11864-000-0011-3
Anahtar Kelimeler : Overall Survival, Acute Myeloid Leukemia, Cytarabine, Daunorubicin, Main Drug Interaction
ISSN: 1527-2729 1534-6277
Sayı: 1
Cilt: 1
Sayfa: 9-17
Sınıflandırma :
19
Secondary acute myeloid leukemia occurring after successful treatment of acute promyelocytic leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
International Journal of Hematology
Yazar(lar) :
Junfa Chen , Zhiyin Zheng , Jianping Shen , Leijun Peng , Haifeng Zhuang , Wenbin Liu , Yuhong Zhou
Konu :
Hematology
Yıl :
2012
Secondary acute myeloid leukemia occurring after successful treatment of acute promyelocytic leukemia Acute Lymphoblastic Leukemia Acute Promyelocytic Leukemia Secondary Acute Myeloid Leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1007/s12185-012-1019-8
Anahtar Kelimeler : Acute Lymphoblastic Leukemia, Acute Promyelocytic Leukemia, Bone Marrow Biopsy, Arsenic Trioxide, Secondary Acute Myeloid Leukemia
ISSN: 0925-5710 1865-3774
Sayı: 3
Cilt: 95
Sayfa: 327-328
20
Frontline treatment of acute myeloid leukemia in adults
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Critical Reviews in Oncology/Hematology
Yayıncı:
Elsevier
Yazar(lar) :
Gevorg Tamamyan , Tapan Kadia , Farhad Ravandi , Gautam Borthakur , Jorge Cortes , Elias Jabbour , Naval Daver , Maro Ohanian , Hagop Kantarjian , Marina Konopleva
Yıl :
2017
Frontline treatment of acute myeloid leukemia in adults Recent years have highlighted significant progress in understanding the underlying genetic and epigenetic signatures of acute myeloid leukemia(AML). and for specific subsets, the improvements are even more dramatic; for example, in acute promyelocytic leukemia, the use of all-trans retinoic acid and AML treatment was also recently influenced by the discovery of the superiority of regimens with higher dose Ara-C and nucleoside analogues compared with Acute myeloid leukemia Frontline treatment
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Recent years have highlighted significant progress in understanding the underlying genetic and epigenetic signatures of acute myeloid leukemia(AML). Most importantly, novel chemotherapy and targeted strategies have led to improved outcomes in selected genetic subsets. AML is a remarkably heterogeneous disease, and individualized therapies for disease-specific characteristics (considering patients’ age, cytogenetics, and mutations) could yield better outcomes. Compared with the historical 5-to 10-year survival rate of 10%, the survival of patients who undergo modern treatment approaches reaches up to 40–50%, and for specific subsets, the improvements are even more dramatic; for example, in acute promyelocytic leukemia, the use of all-trans retinoic acid and arsenic trioxide improved survival from 30 to 40% up to 80 to 90%. Similar progress has been documented in core-binding-factor-AML, with an increase in survival from 30% to 80% upon the use of high-dose cytarabine/fludarabine/granulocyte colony-stimulating factor combination regimens. AML treatment was also recently influenced by the discovery of the superiority of regimens with higher dose Ara-C and nucleoside analogues compared with the “7 + 3”regimen, with about a 20% improvement in overall survival. Despite these significant differences, most centers continue to use the “7 + 3” regimen, and greater awareness will improve the outcome. The discovery of targetable molecular abnormalities and recent studies of targeted therapies (gemtuzumab ozagomycin, FLT3 inhibitors, isocitrate dehydrogenase inhibitors, and epigenetic therapies), future use of checkpoint inhibitors and other immune therapies such as chimeric antigen receptor T-cells, and maintenance strategies based on the minimal residual disease evaluation represent novel, exciting clinical leads aimed to improve AML outcomes in the near future.
DOI : 10.1016/j.critrevonc.2016.12.004
Anahtar Kelimeler : Acute myeloid leukemia, Frontline treatment, High dose Ara-C, Nucleoside analogues
ISSN: 1040-8428
Cilt: 110
Sayfa: 20-34
Sınıflandırma :
Hematoloji %100
21
Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
memo - Magazine of European Medical Oncology
Yazar(lar) :
Mirella Ampatzidou , Charikleia Kelaidi , Michael N. Dworzak , Sophia Polychronopoulou
Konu :
Oncology, Hematology
Yıl :
2017
Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia At the therapeutic intersection between children and older adults, the treatment of adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) poses unique challenges due to their dismal outcome. Intensification of supportive care while maintaining treatment intensity could further improve outcomes of AYAs with leukemia. Adolescents and young adults (AYAs) Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML)
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
At the therapeutic intersection between children and older adults, the treatment of adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) poses unique challenges due to their dismal outcome. In this brief review, we report on the biological features, clinical characteristics and treatment results of a pediatric and AYAs cohort of ALL and AML, treated in our department over a 15-year period. Additionally, we review the recent insights into disease biology, clinical, cytogenetic and molecular characteristics and differences between pediatric patients and AYAs with ALL and AML. In AYAs with ALL, most retrospective trials demonstrated a benefit of pediatric inspired regimens versus adult protocols. Translating the promising pediatric results to the AYAs subgroup, these patients can be successfully treated with risk-adjusted and minimal residual disease (MRD)-guided intensified chemotherapy, with survival rates that can surpass 70%. In AYAs the AML disease is genetically positioned more on the side of adult AML than on that of younger children, but also carries its own specific abnormalities, such as NUP98-NSD1. Toxicity may complicate all phases of treatment (induction and post-induction chemotherapy, hematopoietic stem cell transplantation-HSCT) and accounts for increased mortality, which counterbalances reduced cumulative incidence of relapse (CIR), in comparison with younger children. Intensification of supportive care while maintaining treatment intensity could further improve outcomes of AYAs with leukemia. Cooperative efforts between pediatric and adult hematologists are needed in order to further improve survival of AYAs with ALL and AML.
DOI : 10.1007/s12254-017-0345-1
Anahtar Kelimeler : Adolescents and young adults (AYAs), Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Pediatric hematology-oncology
ISSN: 1865-5041 1865-5076
Sayı: 1
Cilt: 11
Sayfa: 47-53
22
MicroRNA Expression Signatures Accurately Discriminate Acute Lymphoblastic Leukemia from Acute Myeloid Leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
JSTOR
Dergi:
Proceedings of the National Academy of Sciences of the United States of America
Yayıncı:
National Academy of Sciences
Yazar(lar) :
Shuangli Mi , Jun Lu , Miao Sun , Zejuan Li , Hao Zhang , Mary Beth Neilly , Yungui Wang , Zhijian Qian , Jie Jin , Yanming Zhang , Stefan K. Bohlander , Michelle M. Le Beau , Richard A. Larson , Todd R. Golub , Janet D. Rowley , Jianjun Chen
Konu :
Biological Sciences, Science & Mathematics, General Science
Yıl :
2007
MicroRNA Expression Signatures Accurately Discriminate Acute Lymphoblastic Leukemia from Acute Myeloid Leukemia Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, whereas acute myeloid leukemia (AML) is the most common acute leukemia in adults To understand the distinct mechanisms in leukemogenesis between ALL and AML and to identify markers for diagnosis and treatment, we performed a large-scale The differential expression patterns of these four miRNAs were validated further through large-scale real-time PCR on 98 acute leukemia samples covering
Yayıncı Web Sitesi
Kaydet Alıntıla
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, whereas acute myeloid leukemia (AML) is the most common acute leukemia in adults. In general, ALL has a better prognosis than AML. To understand the distinct mechanisms in leukemogenesis between ALL and AML and to identify markers for diagnosis and treatment, we performed a large-scale genome-wide microRNA (miRNA, miR) expression profiling assay and identified 27 miRNAs that are differentially expressed between ALL and AML. Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML. The differential expression patterns of these four miRNAs were validated further through large-scale real-time PCR on 98 acute leukemia samples covering most of the common cytogenetic subtypes, along with 10 normal control samples. Furthermore, we found that overexpression of miR-128 in ALL was at least partly associated with promoter hypomethylation and not with an amplification of its genomic locus. Taken together, we showed that expression signatures of as few as two miRNAs could accurately discriminate ALL from AML, and that epigenetic regulation might play an important role in the regulation of expression of miRNAs in acute leukemias.
Cilt: 104
Sayı: 50
Sayfa: pp. 19971-19976
Yayın Tarihi: 2007-12-11
ISSN: 0027-8424
23
Treatment results of childhood acute myeloid leukemia in Serbia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
memo - Magazine of European Medical Oncology
Yazar(lar) :
Krstovski Nada , Kuzmanovic Milos , Vujic Dragana , Dokmanovic Lidija , Micic Dragan , Slavkovic Bojana , Skoric Dejan , Lazic Jelena , Jovanovic Ankica , Jovic Milena , Konstantinidis Nada , Kostic Gordana , Rodic Predrag , Janic Dragana
Konu :
Oncology, Hematology
Yıl :
2013
Treatment results of childhood acute myeloid leukemia in Serbia We present the results of a retrospective study of acute myeloid leukemia (AML) treatment in Serbia in the period 2000–2012. Treatment was performed in four centers, two of which were located in Belgrade, one in Nis, and one in Novi Sad. Children affected by non- acute promyelocytic leukemia (non-APL) subtypes received treatment regimens derived from protocols of Berlin Frankfurt Munster Acute myeloid leukemia Children Treatment
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
We present the results of a retrospective study of acute myeloid leukemia (AML) treatment in Serbia in the period 2000–2012. Treatment was performed in four centers, two of which were located in Belgrade, one in Nis, and one in Novi Sad. Children affected by non-acute promyelocytic leukemia (non-APL) subtypes received treatment regimens derived from protocols of Berlin Frankfurt Munster AML study group, whereas children with APL were treated according to the AIEOP/GIMEMA ATRA plus Idarubicin “AIDA” protocol. Total number of patients was 106, out of whom 48 were girls (45.3 %) and 58 boys (54.7 %); median age at diagnosis was 9.0 years (range 1 month–17.9 years). In total, 82.1 % of patients achieved complete remission after induction treatment. Twelve patients (11.3 %) died during induction, before achieving complete remission; there were nine deaths during remission (10.5 %) and 20 patients relapsed (23.2 %). Median time of follow-up was 54 months. Two patients (1.9 %) were lost to follow-up. Event-free survival was 50.3 % and overall survival was 58.9 %.
DOI : 10.1007/s12254-012-0051-y
Anahtar Kelimeler : Acute myeloid leukemia, Children, Treatment, Serbia
ISSN: 1865-5041 1865-5076
Sayı: 1
Cilt: 6
Sayfa: 63-68
24
Targeting LSD1 for acute myeloid leukemia (AML) treatment
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Pharmacological Research
Yayıncı:
Elsevier BV
Yazar(lar) :
Shujing Zhang , Menghan Liu , Yongfang Yao , Bin Yu , Hongmin Liu
Yıl :
2021
Targeting LSD1 for acute myeloid leukemia (AML) treatment Targeted therapy for acute myeloid leukemia (AML) is an effective strategy, but currently there are very limited therapeutic targets for AML treatment. invasion of cancer cells, and is associated with poor prognosis. and IMG-7289 in clinical trials. AML treatment
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Targeted therapy for acute myeloid leukemia (AML) is an effective strategy, but currently there are very limited therapeutic targets for AML treatment. Histone lysine specific demethylase 1 (LSD1) is highly expressed in many cancers, impedes the differentiation of cancer cells, promotes the proliferation, metastasis and invasion of cancer cells, and is associated with poor prognosis. Targeting LSD1 has been recognized as a promising strategy for AML treatment in recent years. Based on these features, in the review, we discussed the main epigenetic drugs targeting LSD1 for AML therapy. Thus, this review focuses on the progress of LSD1 inhibitors in AML treatment, particularly those such as tranylcypromine (TCP), ORY-1001, GSK2879552, and IMG-7289 in clinical trials. These inhibitors provide novel scaffolds for designing new LSD1 inhibitors. Besides, combined therapies of LSD1 inhibitors with other drugs for AML treatment are also highlighted.
DOI : 10.1016/j.phrs.2020.105335
Anahtar Kelimeler : Histone demethylase, AML treatment, LSD1 inhibitors, Tranylcypromine derivatives, Combination therapy
ISSN: 1043-6618
Cilt: 164
Sayfa: 105335
25
Treatment Strategies for Therapy-related Acute Myeloid Leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Clinical Lymphoma Myeloma and Leukemia
Yayıncı:
Elsevier
Yazar(lar) :
Prajwal Dhakal , Bimatshu Pyakuryal , Prasun Pudasainee , Venkat Rajasurya , Krishna Gundabolu , Vijaya Raj Bhatt
Yıl :
2020
Treatment Strategies for Therapy-related Acute Myeloid Leukemia Prospective evidence for management of therapy-related acute myeloid leukemia (t-AML) is limited, with evidence extrapolated from major AML trials. Optimal treatment is challenging and needs consideration of patient-specific, disease-specific, and therapy-specific factors. Ongoing clinical trials focusing on treatment of t-AML, including targeted agents and immunotherapy, bode well for the future. Clinical Lymphoma Myeloma and Leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Prospective evidence for management of therapy-related acute myeloid leukemia (t-AML) is limited, with evidence extrapolated from major AML trials. Optimal treatment is challenging and needs consideration of patient-specific, disease-specific, and therapy-specific factors. Clinical trials are recommended, especially for unfit patients or those with unfavorable cytogenetics or mutations. CPX-351 as an upfront intensive chemotherapy is preferred for fit patients; venetoclax with decitabine or azacitidine is an option for patients unfit for intensive chemotherapy. Hematopoietic cell transplant, the only curative option, should be offered to eligible patients with intermediate or unfavorable t-AML or patients with good-risk AML with minimal residual disease. Ongoing clinical trials focusing on treatment of t-AML, including targeted agents and immunotherapy, bode well for the future.
DOI : 10.1016/j.clml.2019.12.007
ISSN: 2152-2650
Sayı: 3
Cilt: 20
Sayfa: 147-155
Sınıflandırma :
Hematoloji %100
26
Progress in the treatment of acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Cancer
Yazar(lar) :
Farhad Ravandi , Alan K. Burnett , Edward D. Agura , Hagop M. Kantarjian
Konu :
Cancer Research, Oncology
Yıl :
2007
Progress in the treatment of acute myeloid leukemia Significant progress in understanding the mechanisms leading to the development of acute myeloid leukemia (AML) has led to the identification of numerous Over the same period, large trials have established standard regimens combining cytotoxic agents for the treatment of patients with AML. newer agents with specific and targeted activity into our standard regimens, Herein the recent developments in the diagnosis and treatment of AML are
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Significant progress in understanding the mechanisms leading to the development of acute myeloid leukemia (AML) has led to the identification of numerous molecular abnormalities that may be responsible for leukemogenesis. Over the same period, large trials have established standard regimens combining cytotoxic agents for the treatment of patients with AML. Current research is attempting to better stratify patients by identifying risk factors responsible for resistance, and to discern ways for incorporating newer agents with specific and targeted activity into our standard regimens, Herein the recent developments in the diagnosis and treatment of AML are reviewed. Cancer 2007. © 2007 American Cancer Society.
DOI : 10.1002/cncr.23000
ISSN: 0008-543X
Sayı: 9
Cilt: 110
Sayfa: 1900-1910
Sınıflandırma :

Yayın Yılı

Sınırla

Doküman Türü
Tümü

Veri Tabanı
Tümü

Dergi İsmi
Tümü

Disiplin
Tümü

Disipline Göre İlgililik

Alt Disiplin
Tümü

Konu
Tümü

Yayıncı
Tümü

Lisan
Tümü

X
Filtreler